Wider loss pressures shares. CRISPR Therapeutics AG (CRSP) reported a loss of $1.37 per share for Q4 2025, wider than the expected loss of $1.23 per share. The loss widened by 11.7% versus consensus, marking a deterioration from Q3 2025’s $1.17 loss that had narrowed expectations by 9.2%. Shares plunged 10.2% to $52.80 on volume of 9.4 million, more than triple the typical daily turnover. The biotech reported a net loss of $130.6 million for the quarter.
Zero revenue compounds the problem. The company recorded no revenue for Q4 2025, unchanged from the prior quarter. Gross profit came in at negative $53.7 million as cost of revenue totaled $53.7 million despite the absence of sales. Operating loss reached $154.8 million, driven by $83.5 million in research and development expenses and $18.4 million in selling, general and administrative costs. EBITDA stood at negative $149.1 million. The company burned $92.6 million in operating cash flow and $93.1 million in free cash flow during the quarter.
Balance sheet remains the lifeline. CRISPR closed the quarter with $347.6 million in cash and cash equivalents against $206.7 million in total debt, leaving working capital of $1.84 billion. Total assets stood at $2.27 billion with stockholders’ equity of $1.92 billion. The sequential deterioration in loss per share—from $1.17 in Q3 to $1.37 in Q4—and the continued absence of revenue raise questions about the timeline to commercialization for the gene-editing specialist’s pipeline.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post CRISPR Therapeutics (CRSP) Reports Wider Q4 Loss of $1.37/Share on Zero Revenue; Shares Plunge 10% first appeared on Alphastreet.
